Immune response to infection with Mycobacterium ulcerans.

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog (2007) 1.83

Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 1.77

Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun (2005) 1.59

Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun (2002) 1.54

Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med (2007) 1.48

Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun (2004) 1.48

Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun (2006) 1.45

Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun (2007) 1.40

Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun (2004) 1.34

Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep (2008) 1.32

Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis (2008) 1.27

Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol (2006) 1.26

Family relationship, water contact and occurrence of Buruli ulcer in Benin. PLoS Negl Trop Dis (2010) 1.16

The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol (2006) 1.13

Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis. Clin Vaccine Immunol (2006) 1.12

Cytokine responses to stimulation of whole blood from patients with Buruli ulcer disease in Ghana. Clin Diagn Lab Immunol (2005) 1.11

Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol (2002) 1.08

Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08

Diagnosis of Mycobacterium tuberculosis infection using ESAT-6 and intracellular cytokine cytometry. Clin Exp Immunol (2005) 1.07

Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009) 1.05

The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER. PLoS Pathog (2014) 1.05

Incidence, clinical spectrum, diagnostic features, treatment and predictors of paradoxical reactions during antibiotic treatment of Mycobacterium ulcerans infections. BMC Infect Dis (2013) 1.04

Impact of human immunodeficiency virus on the severity of buruli ulcer disease: results of a retrospective study in cameroon. Open Forum Infect Dis (2014) 1.00

Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun (2010) 1.00

IFN-gamma induces the erosion of preexisting CD8 T cell memory during infection with a heterologous intracellular bacterium. J Immunol (2008) 1.00

BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis (2011) 0.98

Improved protective efficacy of a species-specific DNA vaccine encoding mycolyl-transferase Ag85A from Mycobacterium ulcerans by homologous protein boosting. PLoS Negl Trop Dis (2008) 0.96

Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination. PLoS One (2012) 0.92

Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response. Infect Immun (2006) 0.89

Immunoglobulin M antibody responses to Mycobacterium ulcerans allow discrimination between cases of active Buruli ulcer disease and matched family controls in areas where the disease is endemic. Clin Diagn Lab Immunol (2004) 0.87

Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity. PLoS One (2010) 0.85

Systemic and local interferon-gamma production following Mycobacterium ulcerans infection. Clin Exp Immunol (2007) 0.84

Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas. Clin Exp Immunol (2009) 0.81

Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer. PLoS Negl Trop Dis (2016) 0.80

Mycobacterium ulcerans in the Elderly: More Severe Disease and Suboptimal Outcomes. PLoS Negl Trop Dis (2015) 0.76

Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer. PLoS Negl Trop Dis (2015) 0.76

Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression. PLoS Negl Trop Dis (2017) 0.75

Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65

A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med (1996) 7.66

Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science (1999) 6.37

Mycobacterium ulcerans infection. Lancet (1999) 4.52

A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun (2000) 3.27

IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. Curr Opin Immunol (1999) 2.69

Heterogeneous antibody responses in tuberculosis. Infect Immun (1998) 2.54

The emergence of Mycobacterium ulcerans infection near Melbourne. Med J Aust (1996) 2.15

The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol (1999) 2.03

The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection. J Hyg (Lond) (1975) 2.02

Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis (2000) 1.58

Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease. Emerg Infect Dis (2000) 1.32

Diversity of antigen recognition by serum antibodies in experimental bovine tuberculosis. Infect Immun (1998) 1.30

Proliferation of distinct human T cell subsets in response to live, killed or soluble extracts of Mycobacterium tuberculosis and Myco. avium. Clin Exp Immunol (1996) 1.13

Distribution of surface-exposed antigenic glycolipids in recent clinical isolates of Mycobacterium tuberculosis. Res Microbiol (1997) 0.94

Inheritable defects in interleukin-12- and interferon-gamma-mediated immunity and the TH1/TH2 paradigm in man. Allergy (1999) 0.91

Circulating immune complexes in human tuberculosis sera: demonstration of specific antibodies against Mycobacterium tuberculosis glycolipid (DAT, PGLTb1, LOS) antigens in isolated circulating immune complexes. Eur J Clin Invest (1997) 0.88

Mycobacterial crossreactivity of M. tuberculosis reactive T cell clones from naturally converted PPD positive healthy subjects. FEMS Immunol Med Microbiol (1998) 0.86

Emergence of multiply resistant pneumococci. N Engl J Med (1978) 8.32

Traditional enteropathogenic Escherichia coli of infantile diarrhea. Rev Infect Dis (1987) 4.01

Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol (1997) 3.96

Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect Immun (1987) 3.96

Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J Clin Microbiol (1999) 3.96

Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther (1972) 3.78

Enteropathogenic Escherichia coli enteritis: evaluation of the gnotobiotic piglet as a model of human infection. Gut (1985) 3.43

Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28

Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol (1997) 2.88

Identification of a novel genetic locus that is required for in vitro adhesion of a clinical isolate of enterohaemorrhagic Escherichia coli to epithelial cells. Mol Microbiol (2000) 2.85

Mycobacterium ulcerans in wild animals. Rev Sci Tech (2001) 2.84

Antimicrobial susceptibility testing of pneumococci. 2. Determination of optimal disc diffusion test for detection of penicillin G resistance. J Antimicrob Chemother (1980) 2.73

Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol (2000) 2.59

Differentiation between virulent and avirulent Yersinia enterocolitica isolates by using Congo red agar. J Clin Microbiol (1983) 2.52

Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect Immun (1985) 2.48

A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans. J Clin Microbiol (2000) 2.43

Surgical significance of the bile duct of Luschka. Br J Surg (1989) 2.32

Antimicrobial susceptibility testing of pneumococci: determination of Kirby-Bauer breakpoints for penicillin G, erythromycin, clindamycin, tetracycline, chloramphenicol, and rifampin. Antimicrob Agents Chemother (1979) 2.32

Antiviral activity of arabinosylthymine in herpesviral replication: mechanism of action in vivo and in vitro. Antimicrob Agents Chemother (1977) 2.28

Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res (1991) 2.26

Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods (1986) 2.16

The emergence of Mycobacterium ulcerans infection near Melbourne. Med J Aust (1996) 2.15

Identification of Mycobacterium ulcerans in the environment from regions in Southeast Australia in which it is endemic with sequence capture-PCR. Appl Environ Microbiol (2000) 2.14

EspG, a novel type III system-secreted protein from enteropathogenic Escherichia coli with similarities to VirA of Shigella flexneri. Infect Immun (2001) 2.12

Reduced interferon-gamma secretion in neonates and subsequent atopy. Lancet (1994) 2.08

Universal precautions: attitudes of Australian and New Zealand anaesthetists. Med J Aust (1997) 2.01

Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child (2001) 1.99

Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria. Med J Aust (1999) 1.91

Studies with enteroaggregative Escherichia coli in the gnotobiotic piglet gastroenteritis model. Infect Immun (1992) 1.84

A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect (1997) 1.82

Empowerment: an idea whose time has come in diabetes education. Diabetes Educ (1991) 1.76

Multisite comparison of CD4 and CD8 T-lymphocyte counting by single- versus multiple-platform methodologies: evaluation of Beckman Coulter flow-count fluorospheres and the tetraONE system. The NIAID DAIDS New Technologies Evaluation Group. Clin Diagn Lab Immunol (2000) 1.71

Leukocytosis and natural killer cell function parallel neurobehavioral fatigue induced by 64 hours of sleep deprivation. J Clin Invest (1994) 1.70

Cardiac teratogenesis of halogenated hydrocarbon-contaminated drinking water. J Am Coll Cardiol (1993) 1.68

Assessing the duration of mandibular soft tissue anesthesia. J Am Dent Assoc (1995) 1.66

The pathogenesis of Yersinia enterocolitica infection in gnotobiotic piglets. J Med Microbiol (1985) 1.64

Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells. Microbes Infect (2001) 1.63

Mechanism of action of Yersinia enterocolitica enterotoxin. Infect Immun (1979) 1.61

Enterococcal vanB resistance locus in anaerobic bacteria in human faeces. Lancet (2001) 1.60

Marrow transplantation in chronic granulomatous disease: an update, with 6-year follow-up. J Pediatr (1988) 1.57

Intimin type influences the site of human intestinal mucosal colonisation by enterohaemorrhagic Escherichia coli O157:H7. Gut (2002) 1.55

Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res (1990) 1.54

Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli: case report and review. Clin Infect Dis (1998) 1.53

The Legionella pneumophila F-box protein Lpp2082 (AnkB) modulates ubiquitination of the host protein parvin B and promotes intracellular replication. Cell Microbiol (2010) 1.53

A microbiological study of gastro-enteritis in Black infants. S Afr Med J (1977) 1.51

Generalized infection with Yersinia enterocolitica and the role of iron. Contrib Microbiol Immunol (1979) 1.50

Essential role of YopD in inhibition of the respiratory burst of macrophages by Yersinia enterocolitica. Infect Immun (1994) 1.49

Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res (1986) 1.47

In vitro assessment of virulence in Yersinia enterocolitica and related species. J Clin Microbiol (1985) 1.45

High-dose oral acyclovir reduces the incidence of cytomegalovirus infection in liver transplant recipients. J Infect Dis (1993) 1.45

Clinical manifestations and outcome of Haemophilus influenzae type b disease. J Paediatr Child Health (1995) 1.44

Contribution of urease to acid tolerance in Yersinia enterocolitica. Infect Immun (1995) 1.43

Pathogenic mechanisms of a non-agglutinable Vibrio cholerae strain: demonstration of invasive and enterotoxigenic properties. Infect Immun (1977) 1.43

Mycobacterium ulcerans infection on Phillip Island, Victoria. Med J Aust (1995) 1.42

Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. Antimicrob Agents Chemother (1981) 1.41

Failure to detect conventional enterotoxins in classical enteropathogenic (serotyped) Escherichia coli strains of proven pathogenicity. Infect Immun (1982) 1.40

Adenocarcinoma in situ of the uterine cervix progressing to invasive adenocarcinoma. Aust N Z J Obstet Gynaecol (1996) 1.39

Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst (1986) 1.38

Yersinia enterocolitica isolated from two cohorts of young children in Santiago, Chile: incidence of and lack of correlation between illness and proposed virulence factors. J Clin Microbiol (1991) 1.34

The role of social and cognitive processes in children's adjustment to community violence. J Consult Clin Psychol (1998) 1.33

Transient Brown's syndrome in juvenile chronic arthritis. Ann Rheum Dis (1984) 1.33

Differential secretion of interleukin-8 by human epithelial cell lines upon entry of virulent or nonvirulent Yersinia enterocolitica. Infect Immun (1996) 1.30

Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem (1998) 1.29

Atopic eczema: its impact on the family and financial cost. Arch Dis Child (1997) 1.29

Mycobacterium ulcerans--a mini-review. J Med Microbiol (1999) 1.27

In vitro and in vivo pathogenicity of Plesiomonas shigelloides. Infect Immun (1987) 1.26

Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys (2000) 1.26

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem (1996) 1.24

Immediate food hypersensitivity reactions on the first known exposure to the food. Arch Dis Child (1983) 1.24

Inhibition of neutrophil migration by sera from patients with rheumatoid arthritis. Clin Exp Immunol (1979) 1.23

A newly discovered verotoxin variant, VT2g, produced by bovine verocytotoxigenic Escherichia coli. Appl Environ Microbiol (2003) 1.21

Osteomyelitis and pyogenic sacroiliitis: A difficult diagnosis. J Paediatr Child Health (2004) 1.21

Neonatal septicemia and meningitis due to Aeromonas shigelloides. J Pediatr (1978) 1.21

Summer diarrhoea in African infants and children. Arch Dis Child (1980) 1.20

Identification of virulence-associated characteristics in clinical isolates of Yersinia enterocolitica lacking classical virulence markers. Infect Immun (1998) 1.20

The coiled-coil domain of EspA is essential for the assembly of the type III secretion translocon on the surface of enteropathogenic Escherichia coli. J Biol Chem (1999) 1.18

Quasiparticle spectra, charge-density waves, superconductivity, and electron-phonon coupling in 2H-NbSe2. Phys Rev Lett (2004) 1.16

Equine herpesvirus in vivo: cyclic production of a DNA density variant with repetitive sequences. Virology (1976) 1.16

Identification and characterization of a K88- and CS31A-like operon of a rabbit enteropathogenic Escherichia coli strain which encodes fimbriae involved in the colonization of rabbit intestine. Infect Immun (1997) 1.15

Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med J Aust (2001) 1.15

Age at menarche in athletes and non-athletes. Med Sci Sports (1973) 1.14

Expression of the complement receptors CR1 and CR3 and the type III Fc gamma receptor on neutrophils from newborn infants and from fetuses with Rh disease. Pediatr Res (1990) 1.12

Desferrioxamine and systemic yersiniosis. Lancet (1983) 1.12

Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. Allergy (2010) 1.12

Herpes simplex virus encephalitis in pediatrics: diagnosis by detection of antibodies and DNA in cerebrospinal fluid. Pediatr Infect Dis J (1993) 1.10

Ovarian mucinous tumour with a focus of anaplastic carcinoma: a case report. Pathology (1985) 1.09

Candidacidal mechanisms in the human neonate. Impaired IFN-gamma activation of macrophages in newborn infants. J Immunol (1994) 1.09

Increased Th1 and Th2 allergen-induced cytokine responses in children with atopic disease. Clin Exp Allergy (2002) 1.08

Characterization of the roles of hemolysin and other toxins in enteropathy caused by alpha-hemolytic Escherichia coli linked to human diarrhea. Infect Immun (1998) 1.08